Study of Effectiveness and Safety of Percutaneous Balloon Mitral Valvulotomy for Treatment of Pregnant Patients with Severe Mitral Stenosis

Dr Bhavesh Talaviya¹, Dr Pradeep Deshmukh², Dr Sandeep Chaurasia³, Dr Sunil Washimkar⁴, Dr Mahendra Maske⁵, Dr Mukund Deshpande⁶

Abstract: **Introduction:** Mitral stenosis is the commonest cardiac valvular lesion in pregnant women. When it is present in severe condition it leads to maternal and fetal morbidity and mortality. In mitral stenosis pregnancy can lead to development of heart failure. **Aim:** To evaluate the safety and efficacy of balloon mitral valvulotomy (BMV) in pregnant females with severe mitral stenosis. **Materials and Methods:** A total of 49 pregnant patients who underwent Balloon Mitral Valvulotomy were included in the study from July 2015 to July 2017. Mean age of these of these patients was 25.7 ± 3.1 years. Clinical follow-up during pregnancy was done every 3 months until delivery and after delivery. The mean follow-up time after BMV was 6.7 ± 0.56 months. **Results:** From the 49 pregnant females 24 (46.7%) and 25 (53.3%) patients underwent BMV during the third and second trimester of pregnancy respectively. The mean mitral valve area was increased from 0.93 ± 0.17 cm² to 1.75 ± 0.27 cm² (p<0.0001) immediately after BMV. Pre-procedure peak pulmonary artery pressure was 43.05 ± 15.88 mmHg, which decreased to 22.31 ± 6.36 mmHg (p value <0.0001). Hemodynamic data showed pre-BMV left atrial mean pressure of 29.6 ± 6.6 mmHg, which decreased to 13.7 ± 4.8 mmHg after the procedure (p value <0.0001) but remained very much unchanged at 6.72 month period of follow-up. There was no maternal mortality in our study. One of the patients developed cardiac tamponade and another patient developed severe mitral regurgitation, which were managed medically. The patient who developed severe mitral regurgitation later underwent mitral valve replacement. Post-procedure follow-up showed an improvement in NYHA status by at least one class in 81.3% of patients. Thirty-nine (81.3%) patients had a term normal vaginal delivery and 9 (16.7%) underwent cesarean section for obstetric indications. One of the patients had abortion on the second day of the procedure. **Conclusion:** During pregnancy BMV technique is safe and effective in patients with severe mitral stenosis. This results in marked symptomatic relief and hemodynamic improvement along with long term maternal and fetal outcomes.

Keywords: Cardiac abnormalities, Cardiac valvular, Morbidity and mortality

1. Introduction

Mitral stenosis is the commonest cardiac valvular lesion in pregnant women. Cardiovascular events such as arrhythmia, hypertension and heart failure is responsible for the complication in pregnant women with heart diseases. Obstetric and neonatal complications are seen more frequently in pregnant women with heart disease in comparison to those without heart disease. Worldwide, prevalence of rheumatic heart disease is decreasing but still it is accounted as most important cause of valvular problems, in which mitral stenosis is the commonest lesion. When mitral stenosis is present in severe condition it results into significant risk of morbidity and mortality for both mother and foetus. In adults, mitral stenosis occurs usually due to a post-rheumatic inflammatory and degenerative disease that fuses the mitral commissures and thickens the chordae. It is one of the most frequently encountered cardiac abnormalities in woman of child bearing age, accounting for nearly 90% of the cases of rheumatic heart disease associated with pregnancy.

Maternal mortality from mitral stenosis is approximately 1%, and rises up to almost 7% in patients with severe impairment. Surgery carries a substantial risk of fetal mortality and morbidity. Valve replacement is associated with high rates of fetal loss (23%) and maternal mortality (2.5%), due to complications of coagulation/anticoagulation [2]. Percutaneous balloon valvulotomy is an alternative to surgery and should be considered as a treatment-of-choice in patients with mitral stenosis who remain symptomatic despite adequate medical therapy. The aim of intervention was to evaluate the effectiveness and safety of percutaneous mitral valvulotomy for the treatment of pregnant patients with mitral stenosis.

2. Materials and Methods

**Study design and patient population**

We conducted a prospective study to evaluate the outcomes of percutaneous mitral valvulotomy in pregnant patients with mitral stenosis. Between July 2015 and July 2017, 49 pregnant patients with mitral stenosis underwent balloon mitral valvulotomy (BMV) at our center. BMV was performed in pregnant women with mitral stenosis with following inclusion criteria:

1. Severe or moderate mitral stenosis with valve area 1.0 cm² or less with New York Heart Association (NYHA) functional class II, III or IV.
2. Pliable mitral valve.
3. Gestational age of 20 weeks after the first trimester of pregnancy.
4. Absence of more than grade II/IV mitral regurgitation.
5. Absence of left atrial/left atrial appendage clot.

The patients with moderate mitral regurgitation (grade II/IV) at baseline, echocardiographically confirmed presence of left atrial thrombus, severe aortic or tricuspid valve disease that required surgery, recent thromboembolic stroke, acute infection processes, and asymptomatic moderate to severe mitral stenosis were excluded from the study. All patients underwent detailed transthoracic echocardiographic (TTE) assessment, including 2-dimensional imaging, Doppler studies, and color-flow mapping. The suitability of the valve
for BMV was assessed by morphology of the mitral valve, presence of calcium in the valve commissures, severity of subvalvar pathology, and presence of mitral regurgitation. Transoesophageal echocardiography (TEE) was performed in patients with atrial fibrillation and in those with a suspicion of left atrial clot on transthoracic echocardiography. All subjects gave informed consent, and the risk associated with the procedure was explained, including the risks related to radiation exposure to the fetus. The protocol of the study was reviewed and approved by institutional ethics committee. BMV was performed in the fasting state in the catheterization laboratory. To limit fetal radiation exposure, abdominal and pelvic lead shielding of patients was done (thickness 0.5 mm) from the diaphragm to pubic symphysis, and contrast left ventriculography was not performed. Fluoroscopy was used only when absolutely necessary. The percutaneous Inoue balloon technique was chosen.

**Surgical technique and data collection**

All BMV procedures were performed under local anaesthesia using the trans-septal, anterograde left-sided cardiac approach. Patients underwent heparinization (100U/kg) after trans-septal puncture. Maximum balloon size possible was determined according to patient’s height. Left atrial pressure was recorded before and after the procedure. Stepwise dilatations of 0.5 mm. Echocardiography was performed in the catheterization laboratory to assess the splitting of the commissures. Procedural success was defined as an increase in mitral valve area of 50% over the baseline or a valve area of >1.5 cm², with no significant increase in mitral regurgitation (>2 grades). Clinical follow-up was accomplished by hospital visits every 3 and 6 months after the procedure until delivery. After BMV, all patients were followed up for fetal growth and wellbeing. Clinical and echocardiographic evaluation was performed in all patients at follow-up. After delivery, patients were called for evaluation after 3 and 6 months. The mean follow up time after BMV was 6.73±0.56 months.

**Statistical Analysis**

All data were expressed as mean (standard deviation, SD). The pre- and post-BMV data were compared using t test. A p value of <0.05 was considered statistically significant.

**3. Results**

There were 49 patients during the period who qualified for BMV. Baseline characteristics are shown in Table 1. Mean age of the patient was 25.7 ± 3.1 years. Mean gestational age was 23.5 ± 5.2 weeks (12–36 weeks). Symptomatic status varied from New York Heart Association (NYHA) functional class II–IV (mean 2.5 ± 0.6). Sinus rhythm was noted in 35 (71.43%) of the patients. Fourteen patients (28.57%) had atrial fibrillation. The procedure was successful in 48 patients. Mean two-dimensional MVA increased from baseline value of 0.93 ± 0.17 cm to 1.75 ± 0.27 cm (p value <0.0001). The pre-procedural peak pulmonary arterial pressure (43.05 ± 15.88 mmHg) decreased to 22.31 ± 6.36 mmHg (p value <0.0001). Pre-BMV peak mitral valve gradient assessed by Doppler echocardiography was 26.22 ± 5.95. Based on hemodynamic data, it was found that the pre-BMV left atrial mean pressure (29.6 ± 6.6 mmHg), reduced to 13.7 ± 4.8 mmHg after the procedure (p value <0.0001). Table 2 shows the pre-BMV and post-BMV comparison. The mean fluoroscopy time was 6.4 ± 1.2 min. There was no maternal mortality in this study. The procedure was successfully completed in 48 patients (95.9%). Cardiac tamponade developed in a patient who underwent a successful valvotomy, and it necessitated a surgical repair of the rent. This patient went on to have a term normal delivery. One patient who developed severe mitral regurgitation was managed medically since she was hemodynamically and symptomatically stable and she also had a normal vaginal delivery subsequently. This patient underwent elective mitral valve replacement later. Post-procedure follow-up showed an improvement in NYHA status by at least one class in 81.3% of patients.

### Table 1: Baseline characteristics of pregnant women who underwent BMV (n = 49).

| Age | 25.69 ± 3.08 (21–33) |
| Gestational age at which BMV is performed | 23.5 ± 5.2 weeks |
| NYHA class | |
| II | 24 (50%) |
| III | 22 (45%) |
| IV | 2 (4.0%) |
| 2D MVA | 0.93 ± 0.17 cm |
| Atrial fibrillation | 14 (28.5%) |

**BMV, balloon mitral valvotomy; MVA, mitral valve area**

### Table 2: Echocardiographic and hemodynamic data before and after BMV.

<table>
<thead>
<tr>
<th>Pre-BMV (mean ± SD)</th>
<th>Post-BMV (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2D MVA</td>
<td>0.93 ± 0.17 cm</td>
</tr>
<tr>
<td>LA mean pressure</td>
<td>29.57 ± 6.53 mmHg</td>
</tr>
<tr>
<td>PAP</td>
<td>43.03 ± 13.88 mmHg</td>
</tr>
<tr>
<td>NYHA class</td>
<td>II–IV (2.5 ± 0.6)</td>
</tr>
<tr>
<td>Peak mitral valve gradient</td>
<td>26.22 ± 5.95 mmHg</td>
</tr>
</tbody>
</table>

BMV, balloon mitral valvotomy; LA, left atrium; PAP, peak pulmonary artery pressure; SD, standard deviation.
Thirty-nine (81.3%) patients had a term normal vaginal delivery and eight (16.7%) had cesarean section for obstetric indications. One patient had an abortion on the second day post-procedure.

Baseline and demographic details of 49 patients with mitral stenosis who underwent balloon mitral valvulotomy, Short-term follow-up information was available in 48 of 49 of the total patient population (90%). One patient was lost to follow up. The mean follow up duration was 6.72 ± 0.56 months. Mean diastolic gradients had decreased significantly after the procedure (p < 0.001) but remained very much unchanged at 6-month follow-up compared with post procedure values.

Two patients had an increase in mitral regurgitation by 2 grades. The mean mitral valve area was 0.93 ± 0.17 cm² before BMV and increased to 1.75 ± 0.27 cm² (p < 0.0001) immediately after BMV. At about 6-month follow-up, the mean mitral valve area decreased from 1.75 to 1.6

About 83.4% of patients had fluoroscopy time between 2 to 6 minutes, while five (16.66%) patients had fluoroscopy time more than 8 minutes. The mean fluoroscopy time of the whole group was 6.44 ± 1.16 min. We did not calculate radiation exposure in any of the patient. Short term follow up information was available in 48 of 49 of the total patient population (98%). Three patients were lost to follow up. The mean follow up duration was 6.72 ± 0.56 months.

There was one abortions, No still births or neonatal deaths. Mean birth weight was 2.52 ± 0.35 kg (range: 1.25 to 3.25). Seven (23.33%) babies were having birth weight less than 2.5 kg. There were no clinically evident congenital malformations in any of the patients. All children had normal mental development with normal development milestones.

4. Discussion

Marked hemodynamic changes and the increased cardiac output have their adverse effects during pregnancy, and can lead to worsening of symptoms by approximately 30 weeks of gestation, during labor and after delivery. Maternal mortality is approximately 1% in untreated patients and depends on the functional class of patients during pregnancy. Studies have shown that open surgical procedures during pregnancy carry an adverse fetal and maternal outcome. Medical management alone does not give adequate symptomatic relief or prevent an adverse outcome. In this context, BMV performed during pregnancy is found to be safe and provides excellent symptomatic relief.

In a study conducted by Mishra et al. in All India Institute of Medical Sciences, India (n = 85), a success rate of 94.1% was noted when BMV was performed in severe mitral stenosis patients of NYHA class III-IV, at a mean gestational age of 24.84 ± 4 weeks. In the present study, majority of patients were in NYHA functional class II–III and the success rate was 98%. In both groups, patients had excellent symptomatic relief and improvements in NYHA class. There was no maternal mortality in both the studies.

Singh et al. from Jayadeva Institute of Cardiovascular Research, Bengaluru, India studied outcome in 58 pregnant patients with mean gestational age of 26.53 ± 5.2 weeks. They reported a success rate of 91% and increase in mean 2D MVA from 0.87 ± 0.14 cm² to 1.82 ± 0.25 cm². No maternal mortality or abortion occurred during this study. Harikrishnan et al. (n = 36) reported a procedural success rate of 97.2% and an excellent symptomatic improvement. There was no maternal mortality in this study, though 3 preterm deliveries were reported. In the present series, 39 (79.3%) patients had term normal vaginal deliveries and 8 (16.7%) had caesarean sections. The mean fluoroscopy time in the study of Harikrishnan et al. was 5.4 ± 5.8 min which were comparable to the present study. Gupta et al. evaluated the safety and efficacy of BMV in 40 pregnant women with rheumatic mitral stenosis. Thirty nine patients underwent a successful procedure. Eleven patients in whom BMV was performed before 20 weeks of gestation underwent medical termination of pregnancy. Out of the 29 women who continued pregnancy, one patient developed preterm labor and one had a stillbirth. There was no maternal mortality in this study. Mean fluoroscopy time was 7.8 ± 1.8 min.

Routray et al. have studied patients undergoing BMV during pregnancy and the long-term effects on child development in them. They performed BMV in 40 pregnant women and 39 of them had successful outcome. After a mean follow-up of 36 ± 15 months, 38 babies maintained normal growth and development except for a single death of a baby at 7th month due to pneumonia. Kinsara conducted a follow-up study in 20 pregnant women who had BMV during pregnancy. Their offspring had mean age of 63 ± 39 months (range: 6–98). All had normal growth and development as assessed by standard development charts and laboratory tests. The above studies show that BMV done during pregnancy had no major adverse effects on the fetus and postnatal growth and development of the offspring. In the present study, out of 49 patients, 47 had a successful procedure with mean fluoroscopy time of 6.44 ± 1.16 min. There were no preterm delivery, but there was an abortion following the procedure. We found excellent symptomatic relief following the procedure without an increased risk of maternal mortality. These results are consistent with previous studies and show that performing BMV during pregnancy in symptomatic mitral stenosis patients is safe and effective with good fetal and maternal outcomes.

5. Conclusion

Percutaneous mitral valvulotomy during pregnancy is safe and provides excellent symptomatic relief and hemodynamic improvement. This should be considered as the treatment of choice when managing pregnant women with severe mitral stenosis.

6. Conflicts of interest

The authors have none to declare.

7. Financial or Other Competing Interests

None
References


